Loading...
Market
What will be the market share of BEYFORTUS® in the US RSV preventive therapy market by the end of 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Market research reports from reputable firms such as IQVIA or Frost & Sullivan
Story
Sanofi and AstraZeneca Win FDA Approval for BEYFORTUS® Manufacturing Line to Protect Babies
Sep 16, 2024, 05:00 PM
Sanofi and AstraZeneca have received approval from the U.S. Food and Drug Administration (FDA) for a manufacturing line dedicated to their preventive respiratory syncytial virus (RSV) therapy. The approval allows Sanofi to begin shipping BEYFORTUS® in the United States, aimed at protecting babies against RSV disease. This development marks a significant step for both companies in their efforts to combat RSV.
View original story
Similar markets
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Pfizer • 25%
GlaxoSmithKline • 25%
Moderna • 25%
Other • 25%
Pfizer's Abrysvo • 25%
Moderna's RSV vaccine • 25%
GSK's RSV vaccine • 25%
Other • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%